
A study examined 193 patients with axial spondyloarthritis (axSpA), predominantly ankylosing spondylitis, to compare clinical characteristics and treatment outcomes between those receiving nonsteroidal anti-inflammatory drugs (NSAIDs) versus advanced therapies. Approximately 44% of patients relied solely on NSAIDs, whereas 56% opted for advanced therapies, primarily TNF inhibitors. Disease activity measures such as BASDAI and ASDAS-CRP indicated generally low disease activity across both treatment groups, with no significant differences in CRP levels or BASDAI scores between NSAID and advanced therapy cohorts. The study underscores positive clinical and radiological outcomes associated with NSAIDs and advanced therapies in the real-world management of axSpA.
Like
Save
Share